Combined olaparib and oxaliplatin inhibits tumor proliferation and induces G2/M arrest and γ-H2AX foci formation in colorectal cancer
Authors Xu K, Chen Z, Cui Y, Qin C, He Y, Song X
Received 24 May 2015
Accepted for publication 4 September 2015
Published 20 October 2015 Volume 2015:8 Pages 3047—3054
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 5
Editor who approved publication: Prof. Dr. Jianmin Xu
Kaiwu Xu,1* Zhihui Chen,2* Yi Cui,1 Changjiang Qin,2 Yulong He,2 Xinming Song2
1Endoscopy Center, 2Gastrointestinal Surgery Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, People’s Republic of China
*These authors contributed equally to this work
Background: Poly (ADP-ribose) polymerase 1 (PARP1) has an important role in homologous recombination repair. The purpose of this study was to investigate the effect of PARP1 inhibitor on oxaliplatin treatment for colorectal cancer (CRC).
Methods: A cell counting kit-8 assay was used to determine the sensitivity of CRC cells to olaparib and/or oxaliplatin. The gene and protein expressions of PARP1 and the gamma histone variant H2AX (γH2AX) were measured by real-time quantitative polymerase chain reaction and western blotting, respectively. The γH2AX foci formation assay was used to investigate the influence of treatments on cells. Flow cytometry was used to examine the changes in cell cycle distribution. Finally, we investigated the combination of olaparib and oxaliplatin in the CRC tumor model.
Results: Olaparib changed the expression of γH2AX and PARP1, and increased the sensitivity of CRC cells to oxaliplatin. The γH2AX foci assay showed that olaparib did not induce double-strand breaks (DSBs) alone, but it enhanced the induction of DSBs by oxaliplatin. The flow cytometry results showed that cells exposed to combination treatment had more G2/M-phase cells than control. Additionally, tumor xenograft studies suggested that combined treatment inhibited the growth of CRC.
Conclusion: CRC cells are sensitized to combined treatment with olaparib and oxaliplatin, and this could be a promising strategy for clinical chemotherapy in CRC.
Keywords: olaparib, oxaliplatin, chemosensitization, colorectal cancer
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]